Home / People / Faculty / Thomas Bader

Thomas Bader ——Professor

Room C504, Building 24, Tianjin University
School of Pharmaceutical Science and Technology
Group weblink
Education Experience
1998 Ph. D. Georg-August-University of Göttingen, Germany
Professional Experience
1998-1999 Postdoctoral Scientist Byk Gulden Lomberg Chemische Fabrik GmbH, Germany
2000-2001 Postdoctoral Scientist Cilag AG, Switzerland
2001-2003 Research Assistant, Project Leader Laboratory for Process Research, University of Zurich, Switzerland
2003-2004 Head of R&D Laboratory Laboratory for Process Research, University of Zurich, Switzerland
2004-2013 Head of Chemistry Laboratory for Process Research, University of Zurich, Switzerland
2013-2014 Senior Research Associate Department of Chemistry, University of Zurich, Switzerland
2015-2017 Scientific Director of PTEC, and Sen. Res. Fellow School of Pharmaceutical Science and Technology, Tianjin University, China
Research Area

The research of the Bader group encompasses Industrial Process Research and Development of chemical projects from bench to GMP production. This includes:

(I) Detailed retrosynthetic analyses of target compounds (predominantly active pharmaceutical ingredients and intermediates thereof), design, compilation, and assessment of non-infringing and innovative route proposals,

(II) Project management including preparation of project plans and cost analyses,

(III) Process research comprising feasibility studies, route-scouting, and selection as well as safety considerations,

(IV) Process development comprising simplification, optimization and refinement of scalable, safe, economic, sustainable and robust processes ready for transfer to production departments, and

(V) Support for GMP compliant manufacturing.

strategy and design 2.jpg

screening and optimization.jpg

Honors and Awards
Bader, T.; Stutz, A.; Bichsel, H.-U.; Fu, C.Methods for Producing Paricalcitol, WO 2010/009879 A2, 2010; US9212136 B2, 2015; EP2334640 B1, 2015.
Suzuki, Y., Lehmann, I., Bichsel, H.-U., Bader, T., Thamapipol, S., Method for the Preparation of Beta-substituted Gamma-amino Carboxylic Acids, WO2015/189068 A1, 2015; US9745249 B2, 2017.
Bader, T. Polymorphic and Pseudopolymorphic Forms of Trandolaprilat, Pharmaceutical Compositions and Methods for Production and Use. WO 2007/113680 A2, 2007; EP2004603 B1, 2013; US7943655 B2, 2011.
Porstmann, F. R.; Horns, S.; Bader, T. Process for Preparing (αS,βR)-6-Bromo-α-[2-(dimethylamino)ethyl]-2-methoxy-α-1-naphthalenyl-β-phenyl-3-quinolineethanol. WO 2006/125769 A1, 2006; EP1888604 B1, 2012; US8039628 B2, 2011; US8350040 B2, 2013.
L. Ling, Bichsel H.-U., Bader T., Bo C., Xianmei Y., Method for Purifying Doxercalciferol, CN101863809 B, 2013.
Bader, T.; Bichsel, H.-U.; Gilomen, B.; Meyer-Wilmes, I.; Sundermeier, M., Polymorphic Forms of Olopatadine Hydrochloride and Methods for Producing Olopatadine and Salts Thereof, WO 2007/110761 A2, 2007; US7687646 B2, 2010.
Bader T., Stutz A., Hofmeier H., Bichsel H.--U., A Process for Preparation of Racemic Nebivolol, WO2008/010022 A2; US7560575 B2, 2009.
Bader T., Furegati M., Jungmann O., Novel Crystalline Forms of Entacapone and Production Thereof, WO2005/063696 A2, 2005.
Pogutter M., Rudolf F., Bichsel H.-U., Bader T., Methods for Producing {N-[1(S)-Carboxy-3-phenylpropyl]-S-alanyl-2S, 3aR, 7aS-octahydroindol-2-carboxylic acid] compounds, WO2005/051909 A1, 2005.
Highlighted Publications
Bader, T. Laboratory for Process Research – Ten Years of Successful Partnership between University of Zurich and the Pharmaceutical Industry. Chimia 2006
ResearcherID Publications
Year Title Author(s) Source Volume
2006 Laboratory for Process Research - Ten years of successful partnership between University of Zurich and the pharmaceutical industry Bader, Thomas Chimia 60
Isolating (alpha-S, beta-R)-6-bromo-alpha-(2-(dimethylamino)ethyl)-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol by optical resolution with chiral 4-hydroxydinaphtho (2,1-d:1’,2’-f)(1,3,2)dioxaphosphepin 4-oxide PORSTMANN F R; HORNS S; BADER T
New crystalline forms, pseudopolymorphic form and polymorphic of Trandolaprilat are angiotensin converting enzyme inhibitors useful to treat high blood pressure, cardiac insufficiency and conditions relating to hypertension BADER T
New crystalline polymorphs of entacapone, useful in treatment of Parkinson’s disease, is a selective inhibitor of catechol-O-methyltransferase BADER T; FUREGATI M; JUNGMANN O
New high bioavailability crystalline forms C and D of entacapone, useful in combination with L-dopa and decarboxylase inhibitor for treating Parkinson’s disease BADER T; FUREGATI M
Preparation of N-substituted alanyl-octahydroindole-2-carboxylic acids, especially the cardiovascular drug trandolapril, from octahydroindole-2-carboxylic acid and N-substituted alanine N-carboxylic anhydride POGUTTER M; RUDOLF F; BICHSEL H; et al.
Preparation of paricalcitol useful for treatment of secondary hyperparathyroidism involves transformation starting from vitamin D2 BADER T; BICHSEL H; FU C; et al.
Preparation of racemic nebivolol involves alkylating substituted chroman derivative with racemic substituted chroman derivative to give nitrogen-protected substituted bis chroman derivatives, and separation, deprotection and removal steps BADER T; STUTZ A; HOFMEIER H; et al.
Preparation of racemic nebivolol useful as antihypertensive agent involves N-alkylating 2-amino-1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)ethanol with ketone in inert organic solvent in presence of base and catalyst BADER T; STUTZ A; HOFMEIER H; et al.
Preparing olopatadine, to treat e.g. allergic rhinitis, comprises reacting dihydroxydibenzoxepin-2-acetic acid, Wittig’s reagent and base followed by adding water, extracting with water-miscible solvent, concentrating and crystallizing BADER T; BICHSEL H; GILOMEN B; et al.
  • 11条记录,1 / 2 页
  • 1
  • 2